Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 1;21(9):3207.
doi: 10.3390/ijms21093207.

Post-Translational Modifications of Transcription Factors Harnessing the Etiology and Pathophysiology in Colonic Diseases

Chao-Yuan Hsu  1   2 , Shin-Huei Fu  1   2 , Ming-Wei Chien  2 , Yu-Wen Liu  3   4 , Shyi-Jou Chen  2   5 , Huey-Kang Sytwu  1   2   3
Affiliations
Review

Post-Translational Modifications of Transcription Factors Harnessing the Etiology and Pathophysiology in Colonic Diseases

Chao-Yuan Hsu et al. Int J Mol Sci. .

Abstract

Defects in mucosal immune balance can lead to colonic diseases such as inflammatory bowel diseases and colorectal cancer. With the advancement of understanding for the immunological and molecular basis of colonic disease, therapies targeting transcription factors have become a potential approach for the treatment of colonic disease. To date, the biomedical significance of unique post-translational modifications on transcription factors has been identified, including phosphorylation, methylation, acetylation, ubiquitination, SUMOylation, and O-GlcNAcylation. This review focuses on our current understanding and the emerging evidence of how post-translational regulations modify transcription factors involved in the etiology and pathophysiology of colonic disease as well as the implications of these findings for new therapeutic approaches in these disorders.

Keywords: O-GlcNAcylation; SUMOylation; acetylation; methylation; phosphorylation; transcription factor; ubiquitination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An overview of regulation for transcription factors T-bet, Gata3, RORγt by post-translational modifications (PTMs) in innate lymphoid cells (ILCs) and T helper cells. Transcription factors T-bet, Gata3 and RORγt are regulated by the post-translational modifications (P: phosphorylation; U: ubiquitination; M: methylation; A: acetylation) and the color differences indicate various modifications on their targets.
Figure 2
Figure 2
An overview of regulation for transcription factors STAT3, IRF4, c-Maf by post-translational modifications in T helper cells. Transcription factors STAT3, IRF4, c-Maf are regulated by the post-translational modifications (P: phosphorylation; O: O-GlcNAcylation; S: SUMOylation; U: ubiquitination) and the color differences indicate various modifications on their targets.
Figure 3
Figure 3
An overview of regulation for transcription factors Blimp-1 and Foxp3 by post-translational modifications in Tr1 and Treg cells. Transcription factors Blimp-1 and Foxp3 are regulated by the post-translational modifications (S: SUMOylation; P: phosphorylation; A: acetylation; U: ubiquitination; O: O-GlcNAcylation) and the color differences indicate various modifications on their targets.
See this image and copyright information in PMC

References

    1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Neurath M.F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 2019;20:970–979. doi: 10.1038/s41590-019-0415-0. - DOI - PubMed
    1. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi: 10.1038/nature07205. - DOI - PubMed
    1. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003;3:521–533. doi: 10.1038/nri1132. - DOI - PubMed

Substances